Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
Ocugen, Inc. (OCGN) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | -32,521,000 | 23.98 M | 64.55 M | 42.97 M | |
| 2022 | -71,189,000 | 24.58 M | 108.63 M | 98.49 M | |
| 2021 | -91,652,000 | 9.94 M | 105.76 M | 102.65 M | |
| 2020 | -21,548,598 | 5.83 M | 27.38 M | 25.88 M | |
| 2019 | -6,036,421 | 5.79 M | 16.81 M | 15.77 M |